Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 10682339
Pharmaceutical compositions directly targeting FKBP52 for the treatment of prostate cancer and methods of using same
granted -
US 10682388
Targeting of PELP1 in cancer therapy
granted -
US 10682425
Engineered B lymphocytes and compositions having micro-RNA and methods for making and using them
granted -
US 10683330
Campylobacter immunogenic compositions and uses thereof
granted -
US 10683366
Methods and compositions for treatment of atherosclerosis
granted -
US 10675348
Antibodies that bind human C6 and uses thereof
granted -
US 10677801
Diagnosis and treatment of breast cancer
granted -
US 10675267
Methods for detection and eradication of myeloid leukemia stem cells
granted -
US 10674901
Minimally-invasive measurement of esophageal inflammation
granted -
US 10676792
Prognostic and diagnostic methods for colorectal cancer
granted -
US 10676527
Methods and compositions for modulation of blood-neural barrier
granted -
US 10676480
Anti-cancer compounds targeting Ral GTPases and methods of using the same
granted -
US 10676759
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10675273
Benzothiazole amphiphiles
granted -
US 10675307
Compositions comprising perivascular stem cells and nell-1 protein
granted -
US 10676534
Vaults engineered for hydrophobic drug delivery
granted -
US 10668085
Thermo-kinetic mixing for pharmaceutical applications
granted -
US 10668118
Microbial consortium and uses thereof
granted -
US 10668161
Therapeutic hyperbranched polyglycerol encapsulated biomolecules
granted -
US 10669320
Mps1 and KNL1 phosphorylation system
granted -
US 10669312
Peptide for suppressing osteoclast differentiation and use thereof
granted -
US 10668002
Anhydrous polysaccharide films
granted -
US 10669516
Methods and apparatus for conditioning cell populations for cell therapies
granted -
US 10668129
Synergistic combination of neuronal viability factors and uses thereof
granted -
US 10668049
Methods of treating cognitive decline with transforming growth factor beta inhibitors
granted -
US 10668015
Unit aerosol doses for anticoagulation
granted -
US 10667994
Bioactive dental restorative material with remineralization properties
granted -
US 10668024
Mesoporous silica nanoparticles for biomedical applications
granted -
US 10669560
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10661095
Photodynamic therapy for use in treating cancer
granted -
US 10662183
Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same
granted -
US 10662161
Pyrimidines and uses thereof
granted -
US 10662295
Trehalose hydrogels for stabilization and delivery of proteins
granted -
US 10660889
Compounds for treatment of cancer
granted -
US 10662215
Cyclic peroxides as prodrugs for selective delivery of agents
granted -
US 10660850
Compositions and methods of making brittle-matrix particles through blister pack freezing
granted -
US 10660895
Methods for treating amyotrophic lateral sclerosis
granted -
US 10660923
Sinusitis diagnostics and treatments
granted -
US 10655183
Carcinoma diagnosis and treatment based on ODC1 genotype
granted -
US 10654864
Modified cytotoxins and their therapeutic use
granted -
US 10654802
Indoline derivatives and method for using and producing the same
granted -
US 10653789
Polymer-drug conjugates for combination anticancer therapy
granted -
US 10654916
Compositions and methods for the treatment of neuromyelitis optica
granted -
US 10653749
Targeting GIV-GEF-GI signaling for treating diverse diseases
granted -
US 10653150
Shelf life and color profile of resin compositions with silver nanoparticles
granted -
US 10653755
Compositions and methods for treatment of homocystinuria
granted -
US 10653803
Cellular micromotors and uses thereof
granted -
US 10653743
Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory